Mirati Therapeutics Company Overview and Leadership

Mirati Therapeutics is a biotechnology company with a focus on developing cancer therapies. The company was founded in 2004.

Mirati Therapeutics is headquartered in San Diego, California. Its leadership team has a strong background in oncology and pharmaceuticals.

At the helm of the company is Stephen L. Bramuza, who serves as the Chief Executive Officer.

Mirati Therapeutics has made significant strides in the industry with its innovative approach to cancer treatment.

The company's acquisition of Redwood Bioscience in 2018 marked a major milestone in its journey.

This acquisition brought Mirati a novel technology platform for the discovery and development of monoclonal antibodies.

Consider reading: Acquisition of Activision Blizzard by Microsoft

Bristol Myers Squibb has made a significant acquisition worth $4.8 billion.

The acquisition is expected to strengthen the company's presence in the biopharmaceutical industry.

This acquisition is a major move for Bristol Myers, marking a significant expansion of its portfolio.

The company aims to leverage the acquired assets to enhance its pipeline and improve patient outcomes.

The acquisition is expected to be completed in the coming months.

Expand your knowledge: Td Cowen Acquisition

Mirati Therapeutics has been making headlines in recent weeks. British billionaire Joe Lewis intends to plead guilty to US charges, according to his lawyer.

Bristol-Myers Squibb has been expanding its portfolio through acquisitions. On January 23, it closed its acquisition of Mirati Therapeutics. Just a day earlier, on January 22, the company completed the acquisition of Mirati Therapeutics from a group of shareholders.

Here's a brief summary of the major events surrounding the acquisition:

Mirati Therapeutics' Krazati lung cancer treatment has also been making waves. On January 10, it received EU conditional marketing authorization.

Mirati Therapeutics is a clinical-stage oncology company. It was founded in 1998.

The company is headquartered in San Diego, California.

Mirati Therapeutics has made significant changes to its leadership team.

The company appointed Charles M. Baum as its President and Chief Executive Officer, effective September 2021. Baum brought over 30 years of experience in the pharmaceutical industry to the role.

Baum's appointment marked a new era for the company, with a focus on accelerating its pipeline of innovative therapies.

Bristol Myers Squibb has completed its acquisition of Celgene, a move that significantly expands its presence in the oncology market.

This deal was first announced in January 2019 and has been in the works for over a year.

The acquisition is expected to bring in new revenue streams for Bristol Myers Squibb, with Celgene's portfolio of cancer treatments adding to its existing lineup.

The deal is valued at around $74 billion, making it one of the largest pharmaceutical deals in recent history.

The integration of Celgene's operations into Bristol Myers Squibb is already underway, with the company working to combine the two businesses.

The acquisition is expected to create a more formidable player in the oncology market, with a broader range of treatments and therapies available to patients.

Bristol Myers Squibb's CEO, Giovanni Caforio, has stated that the acquisition is a key part of the company's strategy to become a leading player in the oncology market.

Related reading: Acquisition of 21st Century Fox by Disney

The acquisition is also expected to bring in new talent and expertise to Bristol Myers Squibb, with Celgene's scientists and researchers joining the company's ranks.

With this acquisition, Bristol Myers Squibb is well-positioned to take advantage of the growing demand for cancer treatments and therapies.

The deal is expected to close in the third quarter of 2020, with the integration of Celgene's operations into Bristol Myers Squibb already underway.

Expand your knowledge: Celgene

Laurie Stelzer, the CFO, has left the company.

She was the Chief Financial Officer.

Her departure is part of a series of executive changes.

The exact reason for her departure is not specified.

Mirati Therapeutics is a biotechnology company that has made significant strides in the market and finance sector. The company's focus on developing innovative cancer therapies has led to increased investor interest and a subsequent rise in its stock price.

In 2020, Mirati Therapeutics went public with an initial public offering (IPO) that raised $250 million. This influx of capital has enabled the company to accelerate its research and development efforts, including the advancement of its lead product candidate, adagrasib.

The company's financial performance has been robust, with revenue growth exceeding 50% in 2022 compared to the previous year. This growth is a testament to the company's ability to execute on its business strategy and drive value for its shareholders.

Broaden your view: Charter School Growth Fund

In the world of equities, some major deals have been making headlines. Bristol Myers has been on a shopping spree, acquiring several companies to expand its portfolio.

Bristol Myers finalized its acquisition of Mirati Therapeutics on January 24th. This move is likely to boost the company's presence in the pharmaceutical market.

On December 26th, Bristol-Myers Squibb acquired RayzeBio, another significant deal in the industry.

Bristol Myers also made a major acquisition on December 22nd, purchasing Karuna Therapeutics for $14 billion. This deal includes Karuna's treatment for schizophrenia.

Here's a brief summary of the deals:

These acquisitions demonstrate Bristol Myers' commitment to expanding its presence in the pharmaceutical market.

Mirati Therapeutics has seen its fair share of analyst upgrades and downgrades in recent months.

Citigroup downgraded Mirati Therapeutics to Neutral from Buy, but raised the price target to $59 from $48 on December 23, 2023.

Stifel downgraded Mirati Therapeutics to Hold from Buy on November 7, 2023, and cut the price target to $59 from $83.

Scotiabank upgraded Mirati Therapeutics to Sector Perform from Sector Underperform on October 10, 2023, and raised the price target to $58 from $24.

TD Cowen downgraded Mirati Therapeutics to Market Perform from Outperform on the same day.

Piper Sandler also downgraded Mirati Therapeutics to Neutral from Overweight on October 10, 2023, but raised the price target to $58 from $45.

Mirati Therapeutics has been making waves in the medical world with its innovative treatments. In January 2024, the European Commission approved KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRASG12C mutation.

Mirati Therapeutics received positive news in November 2023 when the CHMP (Committee for Medicinal Products for Human Use) gave a positive opinion for KRAZATI as a targeted treatment option for patients with advanced NSCLC with a KRASG12C mutation following a re-examination procedure.

Here are some key publications and releases from Mirati Therapeutics:

Mirati Therapeutics also made headlines in November 2023 with an MHRA (Medicines and Healthcare products Regulatory Agency) authorization for a new treatment for rare lung cancer.

Mirati Therapeutics has a strong leadership team in place, with Sandra Ramos-Alves serving as President, a position she took on January 22, 2024.

Sandra Ramos-Alves is not the only high-ranking executive at Mirati Therapeutics, as Kimberly McCutcheon Jablonski is also a key figure, holding the title of Corporate Secretary since January 22, 2024.

Sophia Park is another important member of the team, serving as Corporate Officer/Principal since January 22, 2024.

The company also has a board of directors that includes several key individuals, including Konstantina Katcheves, Sandra Ramos-Alves, and Kimberly McCutcheon Jablonski, all of whom have been directors since January 22, 2024.

Here is a list of the current leadership team at Mirati Therapeutics: